Scott M Dehm
Overview
Explore the profile of Scott M Dehm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
4367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiwari A, Paithane U, Friedlein J, Tashiro K, Saulnier O, Barbosa K, et al.
bioRxiv
. 2025 Mar;
PMID: 40027648
MYC-driven (MYC+) cancers are aggressive and often fatal. MYC dysregulation is a key event in these cancers, but overexpression of MYC alone is not always enough to cause cancer. (),...
2.
Arafa A, Yadav S, Marshall C, Mauer E, Huang M, Yilma B, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 40019487
Background: Germline alterations in homologous recombination repair (gHRR) genes impact the pathogenesis, treatment options, and survival of cancer patients. However, distinct gHRR gene alterations may differentially impact treatment response and...
3.
Sharifi M, Feng E, Rydzewski N, Taylor A, Sperger J, Shi Y, et al.
Mol Oncol
. 2025 Feb;
PMID: 39985777
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we...
4.
Pitzen S, Rudenick A, Qiu Y, Zhang W, Munro S, McCluskey B, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(6):e2415308122.
PMID: 39913208
Inhibiting the androgen receptor (AR) is effective for treatment of advanced prostate cancers because of their AR-dependent luminal epithelial cell identity. Tumors progress during therapy to castration-resistant prostate cancer (CRPC)...
5.
Sharifi M, Sperger J, Taylor A, Tippins K, Reese S, Carreno V, et al.
Cancer Discov
. 2025 Feb;
PMID: 39912912
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance...
6.
Tietz K, McCluskey B, Miller C, Li Y, Munro S, Dehm S
Cell Rep
. 2025 Jan;
44(1):115211.
PMID: 39847481
Localized prostate cancer can be cured by radiation or surgery, but advanced prostate cancer continues to be a clinical challenge. Altered alternative polyadenylation occurs in numerous cancers and can downregulate...
7.
Arafa A, Ludwig M, Tuncer O, Kollitz L, Gustafson A, Boytim E, et al.
Cancers (Basel)
. 2025 Jan;
16(24).
PMID: 39766159
: Prostate cancer treatment has been revolutionized by targeted therapies, including PARP inhibitors, checkpoint immunotherapies, and PSMA-targeted radiotherapies. Despite such advancements, accurate patient stratification remains a challenge, with current methods...
8.
Lyman J, Dehm S
Endocr Relat Cancer
. 2025 Jan;
32(3.
PMID: 39752185
Treatment for castration-resistant prostate cancer (CRPC) primarily involves suppression of androgen receptor (AR) activity using androgen receptor signaling inhibitors (ARSIs). While ARSIs have extended patient survival, resistance inevitably develops. Mechanisms...
9.
Hwang J, Likasitwatanakul P, Deshmukh S, Wu S, Kwon J, Toye E, et al.
Clin Cancer Res
. 2025 Jan;
31(5):936-948.
PMID: 39745364
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain...
10.
Knutson T, Luo B, Kobilka A, Lyman J, Guo S, Munro S, et al.
Nat Commun
. 2024 Dec;
15(1):10648.
PMID: 39663356
Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant...